T
Theresa M. Carbonaro
Researcher at Johns Hopkins University School of Medicine
Publications - 11
Citations - 566
Theresa M. Carbonaro is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Psilocybin & Hallucinogen. The author has an hindex of 6, co-authored 10 publications receiving 288 citations. Previous affiliations of Theresa M. Carbonaro include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Theresa M. Carbonaro,Matthew P. Bradstreet,Frederick S. Barrett,Katherine A. MacLean,Robert Jesse,Matthew W. Johnson,Roland R. Griffiths +6 more
TL;DR: Multiple regression analysis showed degree of difficulty was positively associated, and duration was negatively associated, with enduring increases in well-being, and difficulty of experience was positivelyassociated with dose.
Journal ArticleDOI
Neuropharmacology of N,N-dimethyltryptamine.
TL;DR: DMT appears to have limited neurotoxicity and other adverse effects except for intense cardiovascular effects when administered intravenously in large doses, and may be a useful experimental tool in exploring how the brain works and a useful clinical tool for treatment of anxiety and psychosis.
Journal ArticleDOI
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
TL;DR: Psilocybin andDXM produced similar profiles of subjective experiences, with psilocybin producing relatively greater visual, mystical-type, insightful, and musical experiences, and DXM producing greater disembodiment.
Journal ArticleDOI
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
Frederick S. Barrett,Theresa M. Carbonaro,Ethan Hurwitz,Matthew W. Johnson,Roland R. Griffiths +4 more
TL;DR: This was the first study of the dose effects of psilocybin on a large battery of neurocognitive assessments and evidence of delirium or global cognitive impairment was not observed with either psilocytebin or dextromethorphan.
Journal ArticleDOI
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches:
Albert Garcia-Romeu,Frederick S. Barrett,Theresa M. Carbonaro,Matthew W. Johnson,Roland R. Griffiths +4 more
TL;DR: Recently, growing evidence suggests psilocybin, a naturally occurring psychedelic, is a safe and promising pharmacotherapy for treatment of mood and substance use disorders when administered as a drug.